Villar, 2013, Spain
Amgen, Inc, Manager of Market Access and Value - Los Angeles, CA
Supporting the strategy to ensuring that Amgen's innovative drugs are accessible to patients in Latin America, Canada, Australia, and New Zealand.
On the Fletcher network: For me, Fletcher represented a passport to the rest of the world. There are Fletcherites everywhere. The Fletcher experience goes way beyond graduation. During my time in Boston and since graduating, I have reached out to numerous alumni from Fletcher and Tufts. The response is always warm, helpful, and exciting. Everytime I have the opportunity to talk to alumni, I relive the spirit of Fletcher. I am honored to be part of such a cohesive community, always ready to advice, help, and work together.
Why I chose Fletcher: Before Fletcher, I worked for several private firms in highly regulated markets. It showed me the importance of an in-depth comprehension of the interactions between business and politics in a global context. The partnership between public and private sectors is one of the major challenges for most of the biggest companies worldwide. I chose the Fletcher MIB program because it includes the studies and professional training essential to advance my career: Political Economy, which complements my background in economics; Quantitative Economics; and Business, especially Finance and Accounting as well as advanced management and leadership tools.
El Libro de los Abrazos (Eduardo Galeano)
Seafood and Spanish omelette
Most pressing world issue:
EU debt crisis
Fields of Study
- International Information and Communication
Strategic Management and International Consultancy
Activities involved in at Fletcher
- European Affairs
Education before Fletcher
- Executive Program, European Health Leadership Program, INSEAD Business School
BA, Economics, Universidad Complutense de Madrid
Experience before Fletcher
- GlaxoSmithKline Inc., Manager of Market Access – Madrid, Spain
Cell Signaling Technology, Corporate Strategy and Marketing Associate - Shanghai, China
How -and Why- to Design Innovative Government Affairs Strategies in Biopharmaceuticals